N-Acetyl Selank Amidate
Cognitive & neuro Research only Animal studies
Also called NA-Selank Amidate
Selank with the same end-capping treatment: acetylated at one end, amidated at the other, to resist enzymatic breakdown. The underlying seven-amino-acid sequence and its anti-anxiety activity are unchanged.
Evidence at a glance
- Evidence
- Animal studies — Not yet studied in people
- Status
- Research compound only
- Dosing
- No human study has set a dose
As with the capped Semax, nearly all the supporting evidence belongs to the parent peptide rather than this modified version.
What studies report
- Shares the core sequence of Selank, which reduced anxiety without sedation in Russian trials
- Terminal caps slow enzymatic degradation in lab assays
How it works
Same seven-residue core as Selank, acting on GABA and serotonin signalling and on BDNF. An acetyl cap at one end and an amide at the other slow the enzymes that would otherwise break it down.
Where it acts
BrainThe library groups this compound under Cognitive & neuro. The diagram shows that target, not every tissue it reaches.
Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
In practice Unapproved use
- Preferred by users who find plain Selank too short-acting
Reported real-world use, not evidence and not a recommendation.
Status: Research compound. Not approved.
- Route
- Intranasal spray
- Sequence
- Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2
- Available as
- 20 mg
Search PubMed for N-Acetyl Selank Amidate → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.